Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into the next stage of clinical development. The company recently reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. This milestone marks a significant step toward a potential new treatment for multiple sclerosis, a chronic neurodegenerative disease affecting millions worldwide.
In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. This mechanism of action could provide a novel therapeutic option for patients who currently have limited treatments that target the underlying causes of the disease.
To support the upcoming Phase 2 trial, Quantum BioPharma is strengthening operational support through a planned partnership with Allucent, a clinical research organization, and engagement with neurological specialists. These collaborations are expected to enhance the design and execution of the trial, ensuring robust data collection and analysis. The company's focus on LUCID-MS underscores its commitment to addressing challenging neurodegenerative disorders.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company also holds a stake in Unbuzzd Wellness Inc., which markets an OTC version of its alcohol misuse product. Quantum BioPharma retains ownership of 19.84% of UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The advancement of LUCID-MS into Phase 2 trials represents a critical inflection point for Quantum BioPharma. If successful, the therapy could provide a disease-modifying treatment for multiple sclerosis, addressing a significant unmet medical need. The company's strategic partnerships and robust preclinical data support the potential of LUCID-MS to become a first-in-class therapy. Investors and patients alike will be watching the upcoming trial results closely.
For more information, visit the company's newsroom at https://ibn.fm/QNTM.
